SZGene

Printable version

SZGene - Gene overview of all published SZ-association studies for DAOA

Gene:

DAOA (G72; LG72; SG72)

Protein:

D-amino acid oxidase activator (putative protein LG72; schizophrenia- and bipolar disorder-associated protein G72)

Chromosome:

13 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 21 October 2010

1. Case-Control Studies (by ethnic group)
				SZ Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Bakker, 2006	Netherlands	CL	4 (detail)	308 (-)	IV	-	-	580 (-)	-	Negative
Bass, 2009	UK	CL	8 (detail)	431 (-)	M	-	-	442 (-)	-	Positive
Carrera, 2010	Spain	CL	5 (detail)	301 (33%)	IV	-	52.1 + 15.8 (-)	604 (48%)	37.4 + 12.4 (-)	Negative
Chumakov, 2002	Canada	CL	19 (detail)	213 (-)	IV	-	-	241 (-)	-	Positive
Chumakov, 2002	Russia	CL	13 (detail)	183 (-)	IIIR	-	-	183 (-)	-	Positive
Corvin, 2007	Ireland	CL	5 (detail)	373 (-)	IV	-	-	812 (-)	-	Positive
Jonsson, 2009	Denmark, Norway, Sweden	CL	4 (detail)	837 (42%)	M	26.5 (-)	45.7 (-)	1473 (42%)	44.1 (-)	Negative
Korostishevsky, 2004	Israel	CL	11 (detail)	60 (-)	IV	-	38.6 + 9.5 (18-65)	130 (-)	-	Positive
Ma, 2006	UK (Scotland)	CL	6 (detail)	183 (28%)	IIIR	25.9 + 13.9 (-)	30.3 + 19.1 (-)	182 (42%)	38.3 + 20.4 (-)	Positive
Nicodemus, 2006	USA	CL	6 (detail)	296 (21%)	IV	-	-	370 (51%)	-	Positive
Opgen-Rhein, 2008	USA	CL	11 (detail)	178 (37%)	IV	21.8 (-)	37.8 + 10.5 (-)	144 (44%)	42.8 + 13.1 (-)	Positive
Rethelyi, 2009	Hungary	CL	2 (detail)	280 (54%)	IV	28.6 (-)	37.6 (-)	230 (57%)	39.9 (-)	Negative
Sanders, 2008	USA, Australia	CL	29 (detail)	1870 (31%)	IV	-	-	2002 (53%)	-	Negative
Schumacher, 2004	Germany	CL	7 (detail)	299 (49%)	IV	-	38.6 + 11.9 (-)	300 (60%)	47.1 + 15.2 (-)	Positive
Shinkai, 2007	Canada	CL	9 (detail)	168 (-)	IV	-	-	168 (-)	-	Positive
Vilella, 2007	Spain	PO	7 (detail)	589 (31%)	IV	-	-	615 (48%)	-	Negative
Williams, 2006	UK, Ireland	CL	9 (detail)	709 (29%)	IV	23.6 + 7.7 (-)	41.8 + 13.5 (-)	1416 (48%)	42.4 + 11.1 (-)	Negative
Wood, 2006	USA	CL	19 (detail)	311 (-)	IV	-	-	291 (-)	-	Negative
Asian
Ma, 2006	China	CL	6 (detail)	588 (46%)	IIIR	26.3 + 15 (-)	31.9 + 17.7 (-)	588 (68%)	39 + 20.1 (-)	Positive
Ohi, 2009	Japan	CL	8 (detail)	1774 (44%)	IV	-	45.6 + 15.1 (-)	2092 (51%)	45 + 19.7 (-)	Negative
Shin, 2007	Korea	CL	9 (detail)	388 (49%)	IV	-	42.2 + 8.6 (23-76)	367 (35%)	52.5 + 11 (28-79)	Positive
Wang, 2004	China	CL	6 (detail)	537 (47%)	IIIR	-	41.7 + 17.4 (-)	538 (51%)	38.8 + 15.7 (-)	Positive
Yue, 2006	Overlaps with Yue, 2007	CL	3 (detail)	216 (44%)	10	25.6 (13-53)	30 + 10 (-)	321 (43%)	31 + 11 (-)	n.a.
Yue, 2007	China	CL	4 (detail)	359 (45%)	M	-	29 + 9 (-)	359 (43%)	31 + 11 (-)	Positive

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

2. Family-Based Studies (by ethnic group)
				Affecteds				Unaffecteds
Study	Population	# Polys	# Families	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Fallin, 2005	USA	14 (detail)	263	274 (26%)	IV	19.5 + 4.5 (-)	-	548 (50%)	-	Positive
Goldberg, 2006	USA	11 (detail)	217	230 (-)	IV	-	-	-	-	Negative
Hall, 2004	South Africa	7 (detail)	233	-	IV	-	-	-	-	Positive
Hall, 2004	USA	7 (detail)	210	210 (-)	IV	-	-	420 (50%)	-	Positive
Nicodemus, 2006	Overlaps with Goldberg, 2006	6 (detail)	296	-	IV	-	-	-	-	n.a.
Shinkai, 2007	Canada	9 (detail)	113	113 (-)	IV	19.5 + 5.6 (-)	-	226 (50%)	-	Positive
Asian
Hong, 2006	Taiwan	1 (detail)	216	216 (43%)	IV	-	30.3 + 8.2 (-)	432 (50%)	-	Positive
Liu, 2006	Taiwan	11 (detail)	218	-	IV	-	-	-	-	Negative
Ma, 2009	China	3 (detail)	126	-	IV	-	-	-	-	Positive
Shi, 2008	China	2 (detail)	437	1116 (36%)	IV	-	-	661 (-)	-	Positive
Yue, 2007	China	4 (detail)	237	237 (44%)	M	-	31 + 7 (-)	474 (50%)	-	Positive
Zou, 2005	China	3 (detail)	223	223 (-)	IIIR	-	-	446 (50%)	-	Positive
Other/Mixed
Addington, 2004	USA	8 (detail)	98	98 (-)	M	-	-	-	-	Positive
Korostishevsky, 2006	Palestine (I)	11 (detail)	56	56 (43%)	IV	22 (14-45)	-	112 (50%)	-	Positive
Korostishevsky, 2006	Palestine (II)	11 (detail)	136	136 (22%)	IV	24.5 (17-32)	-	272 (50%)	-	Positive
Korostishevsky, 2006	Palestine (III)	11 (detail)	31	31 (35%)	IV	23 (16-35)	-	62 (50%)	-	Positive
Mulle, 2005	USA	13 (detail)	159	159 (-)	U	-	-	318 (50%)	-	Negative

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine SZ diagnosis -> "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.


SZGene Recent Updates
SZGene Stats Studies: 1727 Genes: 1008 Polymorphisms: 8788 Meta-analyses: 287





			ALSGene
			AlzGene
			MSGene
			PDGene
			SZGene

			An up-to-date collection of all published genetic association studies.






			SRF News SRF Comments Text Size Reset Text Size Email this page







			Research Participants Collaborators